menu
    • menu

    Company profile for Altimmune

    NEW Drugs in Dev: 10
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AltimmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    910 Clopper Road Suite 201S, Gaithersburg, MD 20878
    Telephone
    Telephone
    (240) 654-1450
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://altimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxin-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/altimmune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune Unveils 2025 Financial Results And Business Updates
    Altimmune Unveils 2025 Financial Results And Business Updates

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250009/0/en/Altimmune-Announces-Fourth-Quarter-and-Full-year-2025-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Altimmune To Participate In Upcoming Investor Conferences
    Altimmune To Participate In Upcoming Investor Conferences

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247264/0/en/Altimmune-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Altimmune Completes $75M Common Stock Offering
    Altimmune Completes $75M Common Stock Offering

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229184/0/en/Altimmune-Announces-Closing-of-75-Million-Registered-Direct-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212638/0/en/Altimmune-Receives-FDA-Breakthrough-Therapy-Designation-for-Pemvidutide-in-MASH.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Altimmune eyes phase 3 MASH trial as weight loss deepens
    Altimmune eyes phase 3 MASH trial as weight loss deepens

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208385/0/en/Altimmune-Announces-that-Pemvidutide-Achieved-Key-Measures-of-Success-at-48-Weeks-in-IMPACT-Phase-2b-MASH-Trial.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Altimmune Announces CEO Transition And Succession Plan
    Altimmune Announces CEO Transition And Succession Plan

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196904/0/en/Altimmune-Announces-CEO-Transition-and-Succession-Plan.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search